Altman Peter 4

What Happened

Peter Altman, President & CEO and a director of BioCardia, reported an acquisition of 5,000 shares on Form 4. The filing shows an open‑market or private purchase (code P) of 5,000 shares at $0.85 per share, for a total reported cost of $4,250. This was a purchase (often viewed as a potentially bullish signal), not a sale or option exercise.

Key Details

• Transaction date: 2026-06-09
• Transaction type: Purchase (Form 4 code P) — open‑market or private purchase
• Price and quantity: 5,000 shares at $0.85 per share; total $4,250
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes/plans: No 10b5‑1 plan, tax withholding, or other special footnotes indicated in the supplied data
• Filing timeliness: Form filed 2026-06-09 (same date as transaction in this report)

Context

This was a small-dollar insider purchase by the company’s CEO. Insider buys can be one signal investors watch for, but they are only one data point and do not guarantee future company performance.